Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Июнь 22, 2024
Pancreatic
cancer
is
one
of
the
most
aggressive
forms
cancer,
and
treatment
options
are
limited.
One
therapeutic
approach
to
use
nanoparticles
deliver
active
agent
directly
pancreatic
cells.
Nanoparticles
can
be
designed
specifically
target
cells,
minimizing
damage
healthy
tissues.
Silver
have
unique
ability
absorb
light,
especially
in
near-infrared
(NIR)
region.
In
this
study,
silver
functionalized
with
IgG
molecules
were
synthesized
administered
cell
lines.
Subsequently,
cells
photo-excited
using
a
2
W
808
nm
laser
further
examined
PANC-1
Flow
cytometry
confocal
microscopy
combined
immunochemical
staining
used
examine
interaction
between
The
photothermal
therapy
based
on
IgG-functionalized
induces
dysfunction
Golgi
apparatus,
leading
activation
caspase-3
apoptotic
pathway
ultimately
resulting
cellular
apoptosis.
These
findings
suggest
that
our
proposed
nanoparticle
could
emerge
as
novel
for
cancer.
Pharmaceutics,
Год журнала:
2023,
Номер
15(5), С. 1318 - 1318
Опубликована: Апрель 22, 2023
Pancreatic
cancer
is
fast
becoming
a
global
menace
and
it
projected
to
be
the
second
leading
cause
of
cancer-related
death
by
2030.
adenocarcinomas,
which
develop
in
pancreas’
exocrine
region,
are
predominant
type
pancreatic
cancer,
representing
about
95%
total
tumors.
The
malignancy
progresses
asymptomatically,
making
early
diagnosis
difficult.
It
characterized
excessive
production
fibrotic
stroma
known
as
desmoplasia,
aids
tumor
growth
metastatic
spread
remodeling
extracellular
matrix
releasing
factors.
For
decades,
immense
efforts
have
been
harnessed
toward
developing
more
effective
drug
delivery
systems
for
treatment
leveraging
nanotechnology,
immunotherapy,
conjugates,
combinations
these
approaches.
However,
despite
reported
preclinical
success
approaches,
no
substantial
progress
has
made
clinically
prognosis
worsening.
This
review
provides
insights
into
challenges
associated
with
therapeutics
discusses
strategies
minimize
adverse
effects
current
chemotherapy
options
improve
efficiency
treatment.
Advanced Materials,
Год журнала:
2023,
Номер
36(10)
Опубликована: Апрель 12, 2023
The
incorporation
of
transition
metal
catalysts
(TMCs)
into
nanoscaffolds
generates
nanocatalysts
that
replicate
key
aspects
enzymatic
behavior.
TMCs
can
access
bioorthogonal
chemistry
unavailable
to
living
systems.
These
nanozymes
be
employed
as
in
situ
"factories"
for
generating
bioactive
molecules
where
needed.
generation
effective
requires
co-engineering
the
TMC
and
nanometric
scaffold.
This
review
presents
an
overview
recent
advances
field
nanozymes,
focusing
on
modular
design
both
nanomaterial
catalyst
how
they
synergistically
work
together
uncaging
imaging
therapeutic
agents.
Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 16, 2024
The
combination
of
cuproptosis
and
immune
checkpoint
inhibition
has
shown
promise
in
treating
malignant
tumors.
However,
it
remains
a
challenge
to
deliver
copper
ions
inhibitors
efficiently
simultaneously
Herein,
mitochondria-targeted
nanoscale
coordination
polymer
particle,
Cu/TI,
comprising
Cu(II),
triphenylphosphonium
conjugate
5-carboxy-8-hydroxyquinoline
(TI),
for
effective
induction
programmed
cell
death-1
(PD-L1)
downregulation
is
reported.
Upon
systemic
administration,
Cu/TI
accumulates
tumor
tissues
induce
immunogenic
cancer
death
reduce
PD-L1
expression.
Consequently,
promotes
the
intratumoral
infiltration
activation
cytotoxic
T
lymphocytes
greatly
inhibit
progression
colorectal
carcinoma
triple-negative
breast
mouse
models
without
causing
obvious
side
effects.
Cancer Letters,
Год журнала:
2024,
Номер
585, С. 216640 - 216640
Опубликована: Янв. 28, 2024
Gemcitabine,
a
pivotal
chemotherapeutic
agent
for
pancreatic
ductal
adenocarcinoma
(PDAC),
frequently
encounters
drug
resistance,
posing
significant
clinical
challenge
with
implications
PDAC
patient
prognosis.
In
this
study,
employing
an
integrated
approach
involving
bioinformatic
analyses
from
multiple
databases,
we
unveil
CSNK2A1
as
key
regulatory
factor.
The
patient-derived
xenograft
(PDX)
model
further
substantiates
the
critical
role
of
in
gemcitabine
resistance
within
context
PDAC.
Additionally,
targeted
silencing
expression
significantly
enhances
sensitivity
cells
to
treatment.
Mechanistically,
CSNK2A1's
transcriptional
regulation
is
mediated
by
H3K27
acetylation
Moreover,
identify
activator
autophagy,
and
enhanced
autophagy
drives
resistance.
Silmitasertib,
established
inhibitor,
can
effectively
inhibit
autophagy.
Notably,
combinatorial
treatment
Silmitasertib
demonstrates
remarkable
efficacy
treating
summary,
our
study
reveals
potent
predictive
factor
inhibition
represents
promising
therapeutic
strategy
restore
PDAC,
offering
hope
improved
outcomes.
Bioengineering & Translational Medicine,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 26, 2025
Abstract
Gastrointestinal
cancers,
a
major
global
cause
of
cancer‐related
mortality
and
disease
burden,
are
heterogeneous
group
malignant
aliments
involving
different
organs
the
digestive
system.
The
late
clinical
diagnosis,
genomic
tumor
heterogeneity,
high
complexity
gastrointestinal
microenvironment,
along
with
increasing
treatment
resistance
have
been
recognized
as
main
contributing
factors
to
current
inadequacy
interventions
poor
prognosis
cancer
patients.
In
coming
years,
is
unfortunately
predicted
increase
due
absence
early
detection
effective
therapeutic
options.
Biomembrane‐coated
biomimetic
nanoparticles
(NPs)
recently
appointed
advanced
nanotechnological
tools
for
management
cancers.
These
comprise
not
only
cell‐mimicking
nanodevices
(the
pioneers
this
top‐down
coating
technology),
but
also
exosome
bacterial
mimetics.
Due
their
enhanced
bio‐interfacing
features,
biocompatibility,
immune
evasion,
specific
targetability
tumorous
tissues,
these
nanostructures
successfully
exploited
provide
safer,
effective,
targeted
applications.
This
review
highlights
latest
research
on
biomembrane‐coated
nanosystems
therapy
diagnosis
most
common
deadliest
subtypes
namely
colorectal
cancer,
gastric
liver
esophageal
pancreatic
cancer.
challenges
toward
translation
mentioned.
In
pancreatic
ductal
adenocarcinoma
(PDAC),
stromal
cells
and
matrix
proteins
form
a
dense
physical
barrier
that,
while
preventing
the
outward
spread
of
tumor
cells,
also
limits
penetration
drugs
CD8+
T
inward.
Additionally,
overactivated
TGF-β/SMAD
signaling
pathway
further
promotes
proliferation
immune
suppression.
Therefore,
crossing
preserving
integrity
stroma,
releasing
intratumorally,
remodeling
activating
system
is
promising
drug
delivery
strategy.
this
work,
type
enamine
N-oxides
modified
nanoparticle
was
prepared,
with
stearic
acid-modified
gemcitabine
prodrug
(GemC18)
pSMAD2/3
inhibitor
galunisertib
encapsulated.
The
peripheral
can
trigger
transcytosis
then
respond
to
hypoxia
acidic
microenvironments,
turning
surface
charge
nanoparticles
positive
enhancing
penetration.
released
inhibits
pathway,
reshapes
matrix,
activates
antitumor
immunity,
combines
(Gem)
kill
cells.
Journal of Industrial Textiles,
Год журнала:
2025,
Номер
55
Опубликована: Фев. 21, 2025
Pancreatic
cancer
remains
one
of
the
most
challenging
malignancies
to
treat
due
its
dense
stromal
microenvironment
and
resistance
conventional
therapies.
This
study
introduces
a
novel
localized
drug
delivery
system
design
target
residual
cells
following
surgery.
Electrospun
fibrous
carriers
were
fabricated
using
needle-less
electrospinning
from
polycaprolactone
(PCL),
silk
fibroin
(SF),
their
blend.
Among
these,
PCL
(average
fiber
diameter:
141
±
28
nm)
exhibited
highest
sustained
paclitaxel
(PTX)
release
in
vitro.
Coating
carrier
with
hyaluronic
acid
(HA)
increased
diameter
535
116
nm
modulated
PTX
release,
shifting
an
initial
rapid
phase
uncoated
more
gradual
over
120
hours.
PTX-loaded
HA-coated
electrospun
significantly
reduced
MiaPaCa
cell
viability,
only
13%
viability
at
96
hours
compared
22%
for
non-coated
carrier.
offers
scalable
efficient
solution
delivery,
providing
prolonged
cytotoxic
efficacy,
off-target
effects.
Its
industrial
scaleability,
combined
potential
post-surgical
pancreatic
management,
presents
innovative
approach
minimizing
reliance
on
systemic
chemotherapy
associated
toxicities.
The
use
Nanospider
TM
technology
further
emphasizes
clinical
potential,
future
vivo
studies
needed
confirm
carrier’s
safety,
pharmacokinetics,
therapeutic
benefits.
